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Phenolic glycolipids (PGLs) are polyketide-derived
virulence factors produced byMycobacterium tuber-
culosis, M. leprae, and other mycobacterial patho-
gens. We have combined bioinformatic, genetic,
biochemical, and chemical biology approaches to
illuminate the mechanism of chain initiation required
for assembly of the p-hydroxyphenyl-polyketide
moiety of PGLs. Our studies have led to the identifi-
cation of a stand-alone, didomain initiation module,
FadD22, comprised of a p-hydroxybenzoic acid
adenylation domain and an aroyl carrier protein do-
main. FadD22 forms an acyl-S-enzyme covalent in-
termediate in the p-hydroxyphenyl-polyketide chain
assembly line. We also used this information to de-
velop a small-molecule inhibitor of PGL biosynthesis.
Overall, these studies provide insights into the bio-
synthesis of an important group of small-molecule
mycobacterial virulence factors and support the fea-
sibility of targeting PGL biosynthesis to develop new
drugs to treat mycobacterial infections.
INTRODUCTION
Mycobacterium tuberculosis andM. leprae, the etiologic agents
of tuberculosis and leprosy, respectively, are pathogens with se-
rious impacts on global public health (World Health Organization,
2007a, 2007b). Tuberculosis is one of the top ten leading causes
of death in the world and is responsible for nearly two million
deaths per year. Moreover, the growing incidence of multi-
drug-resistant (MDR) tuberculosis and the emergence of exten-
sively/extremely drug-resistant strains pose a new threat (Aziz
et al., 2006; Centers for Disease Control and Prevention, 2006).
Although leprosy has been controlled effectively using multidrug
therapy, it remains one of the major causes of nontraumaticChemistry & Biologyneuropathy, and there are over three million people with lep-
rosy-derived disabilities worldwide (Agrawal et al., 2005; Britton
and Lockwood, 2004). Furthermore, the emergence of multi-
drug-resistant strains threatens to compromise leprosy control
(Maeda et al., 2001;Matsuoka et al., 2003). Thus, there is a signif-
icant need for new antimycobacterial drugs with novel mecha-
nisms of action.
M. tuberculosis and M. leprae produce diesters of long-
chain methyl-branched fatty acids (e.g., mycocerosic acids)
and long-chain, glycol-containing aliphatic polyketides (e.g.,
phenolphthiocerols and phthiocerols) that are important small-
molecule effectors of virulence (see Onwueme et al. [2005a]
for a review). Members of this family of lipid diesters were first
established as bona fide virulence factors by Cox et al. (1999)
and Camacho et al. (1999). These compounds are noncova-
lently linked to the outer cell wall layer, and are usually referred
to as dimycocerosate esters (DIMs) (Figure 1). DIM variants are
produced also by M. bovis, M. kansasii, M. marinum, M. ulcer-
ans, M. microti, M. africanum, M. haemophilum, and M. gastri
(Onwueme et al., 2005a), all of which are pathogenic to humans
(Katoch, 2004; Velayati et al., 2005). Production of phenolph-
thiocerol-based DIM variants (phenolic glycolipids [PGLs]) (Fig-
ure 1) has been linked to a hyperlethality phenotype in a mouse
model of tuberculosis (Reed et al., 2004) and associated with
more severe clinical manifestations in a rabbit model of
M. tuberculosis meningitis (Tsenova et al., 2005). Conversely,
a PGL-deficient M. bovis mutant is attenuated in a Guinea pig
model of infection (Collins et al., 2005). PGL overproduction
by M. tuberculosis or addition of purified M. tuberculosis
PGLs to macrophages reduces proinflammatory cytokine re-
lease, whereas loss of PGLs correlates with increased cytokine
release by M. tuberculosis-infected macrophages (Reed et al.,
2004). PGLs of M. bovis also reduce proinflammatory cytokine
release (Reed et al., 2004). M. leprae PGLs induce nerve demy-
elination, a primary contributing factor to the nerve function im-
pairment characteristic of leprosy (Rambukkana et al., 2002),
and are involved in bacterial attachment to and invasion of
Schwann cells (Ng et al., 2000). M. leprae PGLs also interfere15, 51–61, January 2008 ª2008 Elsevier Ltd All rights reserved 51
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PGL Biosynthesis and Inhibitionwith antigen-presenting cell function and suppress the prolifer-
ative response of T cells to mitogens (Onwueme et al., 2005a).
PGLs may also contribute to virulence in other mycobacteria,
as evidenced by the recent observation that a DIM-deficient
mutant ofM. marinum is attenuated in a goldfish model of infec-
tion (Ruley et al., 2004).
Biosynthesis of the phenolphthiocerol moiety of the PGLs
involves the Pks15/1-PpsABCDE type I polyketide synthase sys-
tem (Azad et al., 1997; Constant et al., 2002; Kolattukudy et al.,
1997; Minnikin et al., 2002; Trivedi et al., 2004, 2005), a trans-
acting enoyl reductase (Simeone et al., 2007a), and two tailoring
enzymes that convert phenolphthiodiolones to phenolphthiocer-
ols (Onwueme et al., 2005b; Perez et al., 2004; Simeone et al.,
2007b). Feeding experiments with radiolabeled p-hydroxyben-
zoic acid (pHBA) (Daffe and Draper, 1998; Reed et al., 2004) sug-
gest that the p-hydroxyphenyl moiety of the PGLs is derived from
pHBA, and the p-hydroxybenzoyl (pHB) coenzyme A (CoA) thio-
ester has been suggested as the donor of pHBA (Kolattukudy
et al., 1997). Despite this progress, the current model for PGL
assembly does not contemplate a mechanistic hypothesis for
phenolphthiocerol chain initiation. We report herein our investi-
gations of this key step in PGL assembly. Our studies have
revealed that a stand-alone, didomain initiation module activates
and loads pHBA onto the phenolphthiocerol biosynthesis ma-
chinery in a CoA-independent manner. We also report the syn-
thesis and characterization of a small-molecule inhibitor of this
module that blocks PGL production.
RESULTS
Bioinformatic-Guided Identification of the Initiation
Module of the Phenolphthiocerol
Biosynthesis Machinery
We hypothesized that PGL assembly requires formation of
a pHB-AMP species that would either undergo transesterifica-
tion to a pHB-CoA thioester intermediate under the canonical
polyketide biosynthesis pathway (Fischbach and Walsh, 2006;52 Chemistry & Biology 15, 51–61, January 2008 ª2008 Elsevier LtdMoore and Hertweck, 2002), as suggested previously (Kolat-
tukudy et al., 1997), or, alternatively, acylate an aroyl carrier
protein (ArCP) domain thiol directly. The latter case would be in
analogy to the biosynthetic pathways of salicylate-derived
mycobacterial siderophores (Quadri et al., 1998a) and the
3-amino-5-hydroxybenzoate-derived antibiotic, rifamycin B (Ad-
miraal et al., 2001). We performed protein similarity searches
(http://www.ncbi.nlm.nih.gov/blast) with HbaA, a pHB-CoA li-
gase from Rhodopseudomonas palustris (Larimer et al., 2004),
as the query to probe the genomes ofM. tuberculosis,M. leprae,
and M. bovis for possible pHB-AMP and/or pHB-CoA ligases.
FadD22 produced the most significant alignment, and is con-
served in the three species and annotated as a putative fatty
acyl-CoA ligase. Encouragingly, fadD22 is located between
pks15/1, proposed to encode a type I polyketide synthase that
elongates pHBA to form p-hydroxyphenylalkanoate precursors
for PGL biosynthesis (Constant et al., 2002), and a chorismate ly-
ase gene, encoding the enzyme that catalyzes the formation of
pHBA from chorismate (Stadthagen et al., 2005). FadD22 ortho-
logs are also found in M. marinum (Onwueme et al., 2005a) and
M. ulcerans Agy99 (Stinear et al., 2007). The FadD22 orthologs
have 701–708 aa and high sequence identity (73%–100%) (see
Figure S1 in the Supplemental Data available with this article
online).
Each FadD22 ortholog has an adenylation (AMP-binding,
Pfam00501) domain and a 100–150 aa C-terminal extension rel-
ative to known acyl-CoA ligases that contains a putative
40-phosphopantetheine attachment site (Pfam00550; Figure S1),
a hallmark of acyl, aroyl, and peptidyl carrier protein domains.
This suggested that the adenylation domain forms pHB-AMP
and that this intermediate is converted directly to a pHB-
S-FadD22 thioester by attack of the phosphopantetheine thiol
of the ArCP domain (Figure 2A). Thus, we hypothesized that
phenolphthiocerol biosynthesis initiation involves FadD22, a
stand-alone didomain initiation module that catalyzes formation
of a pHB-S-ArCP domain thioester without the intermediacy of
pHB-CoA.Figure 1. Representative Structures of M. tuberculosis Dimycocerosate Esters
The pHBA-derived phenol moiety of the PGLs is highlighted in red.All rights reserved
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Based on our bioinformatic analysis, we predicted that FadD22
is essential for PGL biosynthesis. Conversely, this protein would
not be required for the biosynthesis of non-pHBA-derived DIM
variants based on phthiocerols (PDIMs) and phthiodiolones
(PNDIMs) (Figure 1). To investigate these hypotheses, we con-
structed an M. bovis strain with a fadD22 deletion. To examine
the effect of the deletion on DIM production, we used
[14C]-pHBA feeding to label PGLs or [14C]-propionate feeding to
label both PGLs and PDIMs/PNDIMs (Figure 3A). Analysis of
labeled PGLs and PDIMs/PNDIMs from the parental strain and
DfadD22 isolates revealed that deletion of fadD22 abrogates
PGL production but not PDIM/PNDIM production (Figure 3B).
The DfadD22 strain transformed with pJAM2-FadD22tb (a plas-
mid expressing M. tuberculosis fadD22, identical to M. bovis
fadD22) producedPGLs, thus ruling out thepossibility that the de-
letion prevents expression of pks15/1 or other neighboring genes
required for PGL production (Figure 3B). Conversely, transforma-
tion with the control vector, pJAM2, failed to restore PGL biosyn-
thesis (Figure 3B). In accordance with the fact that PGLs are not
required for growth in vitro, no growth difference was observed
ex vivo between the parental and mutant strains (Figure S2).
In Vitro Validation of the Catalytic Proficiency of FadD22
To begin assessing the catalytic competence of FadD22, we
explored whether nonphosphopantetheinylated (apo) FadD22
(C-terminally hexahistidine-tagged M. marinum ortholog; Fig-
ure S3) was able to synthesize pHB-AMP. In radiolabeling exper-
iments with both [14C]-pHBA (Figure 4A) and [a-32P]-ATP (data
not shown), FadD22 catalyzed the ATP-dependent formationChemistry & Biologyof labeled pHB-AMP as detected by TLC (Rf = 0.5) and con-
firmed by LC-MS (Figure 4A; LC-MS analysis not shown; see
Experimental Procedures). Based on these analyses, we con-
cluded that FadD22 has pHBA adenylation activity. M. marinum
FadD22(S576A), a protein variant with the predicted Ser-576
phosphopantetheinylation site substituted by Ala (Figure S3),
also catalyzed pHB-AMP formation (Figures 4A–4C), indicating
that the conserved Ser is not essential for adenylation activity.
Importantly, addition of CoA to the reactions had no impact on
pHB-AMP formation, nor did it result in the formation of addi-
tional radiolabeled products detectable by TLC. In particular,
pHB-CoA formation was not detected by TLC (Figure 4B) or
LC-MS (data not shown). In contrast, pHB-CoA (Rf = 0.37) forma-
tion was detected in controls with a R. palustris benzoyl-CoA
ligase (Beuerle and Pichersky, 2002) that accepts pHBA as a
substrate (Figure 4B and LC-MS analysis not shown; see Exper-
imental Procedures). As expected, benzoyl-CoA ligase-depen-
dent accumulation of the pHB-AMP intermediate was observed
in absence of CoA (Figure 4B). Overall, these observations
support the view that FadD22 is not a pHB-CoA ligase.
Time courses of pHB-AMP formation by apo-FadD22 and
FadD22(S576A) revealed a maximum pHB-AMP accumulation
corresponding to a pHB-AMP:enzyme ratio of 5, suggesting
only five catalytic turnovers and that adenylation is inhibited by
the acyl-AMP intermediate (Figure 4C). However, the binding
of the intermediate to the enzyme does not appear to be tight
enough to stop adenylate accumulation at 1:1 stoichiometry.
Overall, this is consistent with the fact that mechanistically re-
lated acyl adenylate-forming enzymes bind (noncovalently) their
cognate acyl-AMP intermediates 2–3 orders of magnitude moreFigure 2. Proposed CoA-Independent Initiation of Phenolphthiocerol Biosynthesis Parallels the Mechanism of Rifamycin B and (Carboxy)-
Mycobactin Biosynthesis Initiation
(A) Proposed CoA-independent biosynthesis initiation process required for assembly of the p-hydroxyphenyl-polyketide moiety of PGLs.
(B) Mechanism for biosynthesis initiation of rifamycin B.
(C) Mechanism for biosynthesis initiation of mycobactins and carboxymycobactins. A, adenylation domain; ArCP, aroyl carrier protein domain; pHBA, p-hydroxy-
benzoic acid; Sal, salicylic acid; AHBA, 3-amino-5-hydroxybenzoic acid; pHB- /Sal- /AHB-S-ArCP, p-hydroxybenzoyl- /salicyl- /3-amino-5-hydroxybenzoyl-ArCP
domain thioester. Noncovalent binding of acyl-AMP intermediates to the adenylation domains is indicated with a vertical dotted line. The phosphopantetheinyl
group in the carrier domains is represented by a wavy line.15, 51–61, January 2008 ª2008 Elsevier Ltd All rights reserved 53
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2003; May et al., 2002; Norris and Berg, 1964; Webster, 1963). It
is likely that pHB-AMP is sequestered in the adenylation domain
until transesterification to the ArCP domain liberates the adeny-
lation domain for another catalytic cycle.Figure 3. FadD22 Is Required for PGL Production
but Not for PDIM or PNDIM Production
(A) TLC analysis of DIMs from M. bovis, M. marinum, and
M. kansasii showing incorporation of the label of [14C]-p-
hydroxybenzoic acid (pHBA) in PGLs and [14C]-propionate
(Prop) in PGLs, PDIMs, and PNDIMs. The profile of tripli-
cate labeling experiments (lanes 1, 2, and 3) are shown
in each panel.M. kansasii lacks PDIMsdue to a (phenol)ph-
thiodiolone ketoreductase deficiency.
(B) Radio-TLC analysis demonstrating that fadD22 is re-
quired for PGL production, but not for PDIM/PNDIM pro-
duction. [14C]-labeled apolar lipids of M. bovis strains
wild-type (lane 1), DfadD22 (lane 2), DfadD22 with vector
pJAM2 (lane 3), and DfadD22 with pJAM2-fadD22tb
(pJAM2 expressing FadD22) (lane 4). Indicated TLC elu-
ents were used for PGL and PDIM/PNDIM visualization
as reported (see Experimental Procedures). PE, petroleum
ether; Et2O, diethyl ether. PGLs remain at the origin with
PE/Et2O (9:1, v/v) eluent. PDIMs/PNDIMs run with the
eluent front in CHCl3/MeOH (95:5, v/v).
To investigate whether apo-FadD22 retains
bound pHB-AMP, we examined the enzyme
and [14C]-pHB-AMP elution patterns obtained
when [14C]-pHB-AMP formation reactions were
subjected to size-exclusion chromatography.
pHB-AMP coeluted with the enzyme, rather54 Chemistry & Biology 15, 51–61, January 2008 ª2008 Elsevier Ltdthan following the small-molecule elution profile delineated by
[14C]-pHBA (Figure 4D). Equivalent results were obtained with
FadD22(S576A) (data not shown). We verified that the acyl
adenylate intermediate is stable in solution for at least 2 hr at
37C (Figure S4), thus excluding the possibility that the lackFigure 4. Formation of pHB-AMP by FadD22 and
FadD22(S576A)
(A) TLC analysis of radiolabeled pHB-AMP formation. En-
zymes were included at 5 mM in the reactions. No product
was detected in reaction without enzyme (data not
shown). The mass spectrum of the pHB-AMP product is
shown.
(B) Influence of CoA on pHB-AMP formation. Substrates
and enzymes (5 mM) included in the reactions are indi-
cated. BZLRp, R. palustris benzoyl-CoA ligase.
(C) Time course for pHB-AMP formation by FadD22 (2 mM)
and FadD22(S576A) (2 mM).
(D) FadD22-pHB-AMP association determined by size ex-
clusion chromatography. FadD22 was included at 15 mM
in the reaction. Graphs show means of triplicate reactions
with SEM. Only one of the triplicate reactions is shown in
the representative TLC image below each graph in (A)
and (B). pHB-AMP, black bars; pHB-CoA, white bars.All rights reserved
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rapid hydrolysis of released pHB-AMP. Reasonable stability of
pHB-AMP and comparable intermediates in aqueous solutions
has been reported (Niu et al., 2006). Thus, the elution pattern
of pHB-AMP is in agreement with the formation of a stable,
noncovalent FadD22pHB-AMP complex.
The second step in our proposed initiation mechanism is
transesterification of the p-hydroxybenzoyl moiety from
pHB-AMP to the phosphopantetheinylated (holo) ArCP domain
(Figure 2A). We developed a phosphopantetheinylation assay
based on FlashPlate technology (Brown et al., 1997) (see Sup-
plemental Experimental Procedures) to investigate whether
FadD22 and FadD22(S576A) are targets for phosphopantethei-
nylation. In this assay, we used the phosphopantetheinyl trans-
ferase, Sfp (Quadri et al., 1998b), and probed for incorporation
of [3H]-phosphopantetheinyl group into these proteins. These
studies demonstrated that apo-FadD22 is a substrate for phos-
phopantetheinylation, while FadD22(S576A) is not (Figure 5A).
These results support the presence of a carrier protein domain
in FadD22 and the role of Ser-576 as the modification site. We
also found that FadD22, coexpressed with Sfp (to obtain holo-
FadD22), could not be [3H]-phosphopantetheinylated in vitro
(data not shown), suggesting that Sfp-dependent phosphopan-
tetheinylation of FadD22 in Escherichia coli proceeds with
100% efficiency.
The ability to obtain holo-FadD22 enabled us to explore
whether FadD22 is competent for pHB-S-FadD22 formation
(Figure 2A). This autoacylation was assayed by probing for
covalent incorporation of a [14C]-pHBA-derived label into
purified holo-FadD22. We also examined [14C]-pHBA loading
onto apo-FadD22 and FadD22(S576A). Holo-FadD22 was read-
ily autoacylated in an ATP-dependent and CoA-independent
manner (Figure 5B). Maximum autoacylation reached 100%
(Figure 5D), in agreement with the 100% conversion of apo- to
holo-protein inferred from the phosphopantetheinylation analy-
sis. Conversely, neither apo-FadD22 nor FadD22(S576A) were
capable of autoacylation (Figure 5B). These observations indi-
cate that FadD22 is not phosphopantetheinylated to a meaning-
ful degree in E. coli in the absence of Sfp. Apo-FadD22 and
FadD22(S576A), like holo-FadD22, are able to form pHB-AMP
(Figure 5C), and we attribute their lack of starter unit loading to
the absence of the phosphopantetheine prosthetic group. Over-
all, our studies of FadD22 demonstrate its pHBA adenylation
activity, its apo- to holo-protein conversion by phosphopante-
theinylation, and its self-loading with pHBA.
Design, Synthesis, and Biological Evaluation
of a PGL Biosynthesis Inhibitor
We and others have recently described a nonhydrolyzable mimic
of salicyl-AMP, salicyl-AMS (50-O-[N-salicylsulfamoyl]-adeno-
sine), as a tight-binding inhibitor of salicylic acid adenylation
domains (Ferreras et al., 2005; Miethke et al., 2006; Somu
et al., 2006). Based on this precedent, we postulated that nonhy-
drolyzable pHB-AMP analogs would inhibit the adenylation
domain of FadD22. To evaluate this idea, we synthesized the
pHB-AMP analog 50-O-[N-(4-hydroxybenzoyl)sulfamoyl]-adeno-
sine (2) (pHB-AMS) (Figure 6A and Figure S5), and tested the
activity of this compound in pHB-AMP and pHB-S-FadD22
formation assays and DIM production assays. pHB-AMSChemistry & Biologyinhibited both pHB-AMP formation (IC50 = 6 mM; Figure 6B) and
pHB-S-FadD22 formation (IC50 = 11 mM; Figure 6C) with IC50
values that are less than 10 times the enzyme concentration,
a characteristic of tight-binding inhibitors (Copeland, 2000).
When tested in PGL and PDIM/PNDIM production assays with
Figure 5. FadD22 Is Phosphopantetheinylated and Autoacylated
with the pHBA, whereas FadD22(S576A) Is Not
(A) Time course for in vitro phosphopantetheinylation of wild-type FadD22
(1 mM) and FadD22(S576A) (1 mM).
(B) Autoloading competence of FadD22 and FadD22(S576A) expressed alone
or together with Sfp. Proteins (10 mM) in acylation reactions with the indicated
compositions were bound to the membrane under denaturing conditions for
analysis of covalently bound radiolabel in the proteins. Only holo-FadD22
was competent for autoacylation (upper right quadrant). Triplicate reactions
were spotted on the membrane.
(C) pHB-AMP formation competence of FadD22 (10 mM) and FadD22(S576A)
(10 mM) expressed alone or together with Sfp. TLC excerpt image shows
formed pHB-AMP (or lack thereof) in reactions of the indicated composition.
(D) Time course for holo FadD22 autoacylation. The concentration of the
pHB-S-FadD22 formed was normalized to the concentration of FadD22
(5 mM) in the reaction ([pHB-S-FadD22]/[FadD22]). Means of triplicate reac-
tions with SEM are shown.15, 51–61, January 2008 ª2008 Elsevier Ltd All rights reserved 55
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PGL Biosynthesis and InhibitionM. tuberculosis,M. marinum,M. kansasii, andM. bovis (data not
shown), pHB-AMS strongly inhibited PGL production in all four
species at up to 14- to 48-fold reduction (Figure 7A). Interest-
ingly, this dramatic inhibition of PGL production correlated with
a slight (1.3- to 3.4-fold) increase in PDIM/PNDIM production
(Figure 7A), probably due to augmented availability of enzymes
and building blocks for PDIM/PNDIM assembly arising frommet-
abolic flux redirectioning upon PGL biosynthesis shutdown. We
also demonstrated that increasing the intracellular concentration
of FadD22 or its adenylation domain reduced the effectiveness
of pHB-AMS (Figure 7B). This result is in line with an expected
inhibitor titration effect and provides additional evidence that
the adenylation domain of FadD22 is the cellular target of
pHB-AMS in the PGL pathway.
Since PGLs are dispensable for ex vivo growth, pHB-AMS is
not expected to have antimicrobial activity in vitro. Thus, to as-
sess the selectivity of this compound, we examined its activity
against M. tuberculosis, M. bovis, M. marinum, and M. kansasii.
As expected, pHB-AMS (%800 mM) had no effect on growth in
cultures started with the high inoculum used in the PGL inhibition
experiments described above (OD580 nm = 0.6). Very modest
growth inhibition was detected at the maximum compound con-
centration in M. tuberculosis and M. bovis cultures started with
low inoculum (OD580 nm = 0.001), which affords a more sensitive
setting for antimicrobial activity detection. This suggests that the
inhibitor has only amarginal off-target effect, which is detectable
at a considerably high compound-to-cell ratio. These results
provide important support for the selectivity of pHB-AMS in
targeting mycobacterial PGL biosynthesis.
DISCUSSION
Several mycobacterial pathogens produce PGLs, a family of
surface-exposed bioactive glycolipids that function as small-
molecule effectors in the host-pathogen interplay and contribute
to virulence. The work presented here provides the first insightsFigure 6. pHB-AMS Inhibits FadD22-Catalyzed pHBA
Adenylation and Autoacylation
(A) p-Hydroxybenzoyl-AMP (1) (pHB-AMP) intermediate and its
mimic, 50-O-(N-[4-hydroxybenzoyl]sulfamoyl)adenosine (2) (pHB-
AMS).
(B) Dose-response for inhibition of pHB-AMP formation plotted with
fractional velocity as a function of pHB-AMS concentration.
(C) Dose-response for inhibition of pHB-S-FadD22 formation plot-
ted with fractional velocity as a function of pHB-AMS concentration.
vi and vc, are velocities in inhibitor- and DMSO-containing reactions,
respectively. Data points are means of triplicate reactions.
into the molecular mechanism of phenolphthiocerol bio-
synthesis initiation, a fundamental step in PGL assem-
bly. Our studies led to the identification of FadD22 as
a stand-alone, didomain loading module that is integral
to the phenolphthiocerol biosynthesis machinery.
FadD22 is responsible for CoA-independent activation
and charging of a pHBA starter unit to form pHB-S-
FadD22, the first committed acyl-S-enzyme covalent
intermediate in the phenolphthiocerol chain assembly
line.56 Chemistry & Biology 15, 51–61, January 2008 ª2008 Elsevier LtdOur in silico analysis pointed to the orphan protein, FadD22,
previously annotated as a putative fatty acyl-CoA ligase, as the
lead candidate for the initiation module required for phenolph-
thiocerol biosynthesis. Our genetic analysis has shown that
fadD22 is essential for PGL production and our in vitro analysis
of FadD22 has validated the functionality of its adenylation and
ArCP domains. The catalytic partnership of these two domains
leads to formation of pHB-S-FadD22. We propose that this
charged module primes phenolphthiocerol biosynthesis by
presenting the starter unit for the first extension cycle of the
p-hydroxyphenyl-polyketide formation process. Starter unit ex-
tension is then carried out by the next enzyme in the phenolph-
thiocerol assembly line—probably Pks15/1. Our ability to obtain
pHB-S-FadD22 will facilitate future enzymological studies to
decipher the functional cooperation of this initiation module
with Pks15/1 or other potential enzyme partners in the phenolph-
thiocerol assembly line.
The CoA independence of the phenolphthiocerol biosynthesis
initiation mechanism parallels that observed in the biosynthetic
pathway of rifamycin B (Admiraal et al., 2001). The rifamycin B
system initiation module consists of an adenylation domain for
3-amino-5-hydroxybenzoate and its partner ArCP domain for
formation of a 3-amino-5-hydroxybenzoyl-S-ArCP domain inter-
mediate (Figure 2B). The mechanism of phenolphthiocerol bio-
synthesis initiation is also reminiscent of that observed in the
biosynthesis of the salicylate-capped, hybrid, nonribosomal
peptide-polyketide (carboxy)mycobactin siderophores pro-
duced byM. tuberculosis and otherMycobacterium spp. (Quadri
et al., 1998a). During the biosynthesis of these siderophores,
MbtA catalyzes adenylation of salicylic acid and subsequent
transesterification onto a holo-ArCP domain located at the N ter-
minus of the nonribosomal peptide synthetaseMbtB (Figure 2C).
The parallel, aryl acid-specific, adenylation-ArCP didomain com-
position of the initiation machinery of the phenolphthiocerol and
siderophore pathways suggests an intriguing possible evolu-
tionary relationship between the PGL and the siderophoreAll rights reserved
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didomain architecture differs between these three aryl acid-
specific loading systems. While FadD22 is a stand-alone
didomain module, the rifamycin B system has a didomain initia-
tion module that is part of a larger protein (RifA) containing three
polyketide synthase modules, while the siderophore pathway
features an in trans loading strategy with a stand-alone adenyla-
tion domain and an ArCP domain fused to an additional module
in MbtB (Figure 2).
The mechanistic insights into phenolphthiocerol biosynthesis
initiation provided us with a framework to design a small-mole-
cule inhibitor of PGL biosynthesis, pHB-AMS. The inhibitory ac-
tivity of pHB-AMS in enzymatic and cellular assays affords addi-
tional support for our model of phenolphthiocerol biosynthesis
initiation. These studies also provide proof-of-principle for the
drugability of the PGL pathway and for inhibition of the biosyn-
thesis of a bona fide polyketide virulence factor. It has been sug-
gested that drugs that inhibit the biosynthesis or the function of
virulence factors may be combined with classical antimicrobialsChemistry & Biologyto afford more efficient treatments against infections (Alksne and
Projan, 2000; Clatworthy et al., 2007;Marra, 2004; Quadri, 2007).
It is interesting to speculate that drugs that block PGL biosynthe-
sis may reduce the adaptive fitness of PGL-producingM. tuber-
culosis strains in the human host by eliminating PGL-dependent
immunomodulatory effects. These drugs may also diminish the
ability of M. leprae to invade Schwann cells and cause nerve
function impairment. Thus, pHB-AMS represents an initial lead
compound for exploring the potential therapeutic value of PGL
biosynthesis inhibitors in animal infection models in the future.
SIGNIFICANCE
Mycobacterial PGLs are a family of surface-exposed bioac-
tive glycolipids that function as small-molecule effectors in
the host-pathogen interplay and contribute to virulence. Un-
derstanding the biosynthesis of these and other effectors of
mycobacterial virulence is an important goal, as it may lead
to new therapeutics. The studies reported here illuminateFigure 7. pHB-AMS Inhibits PGL Production
(A) Inhibition of PGL production by pHB-AMS. The dose-response plots show the effect of pHB-AMSon production of PGLs. PGLT/PGLC, ratio of PGL production
in inhibitor-treated (PGLT) to DMSO-treated (PGLC) cultures. Values represent means from triplicate cultures (±SEM). The maximum fold changes induced by
pHB-AMS on PGL, PDIM, and PNDIM production are depicted in the bar graphs. No PDIM fold change is shown for M. kansasii, which is PDIM deficient.
(B) Reduction of the PGL production inhibitory efficacy of pHB-AMS by multicopy suppressor effect. pHB-AMS was tested at the concentration shown against
M. kansasii (Mk) andMk transformed with the indicated plasmids. pCP0, vector; pCP0-FadD22tb, pCP0 expressingM. tuberculosis FadD22; pCP0-FadD22tbAd,
pCP0 expressingM. tuberculosis FadD22 adenylation domain; pCP0-FadD22ml, pCP0 expressingM. leprae FadD22. Data represent means of triplicate cultures
(±SEM).
(C) Effect of pHB-AMS on growth ofM. tuberculosis (Mt, red circles),M. bovis (Mb, blue squares),M. marinum (Mm, green circles), andM. kansasii (Mk, orange
squares). The effect was evaluated on cultures started with the indicated inoculum levels. ODT/ODC, ratio of OD580 nm of inhibitor-treated (ODT) to OD580 nm of
DMSO-treated (ODC) cultures. Means of triplicate cultures (±SEM) are shown.15, 51–61, January 2008 ª2008 Elsevier Ltd All rights reserved 57
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of the phenolphthiocerol moiety of PGLs. Our results sup-
port a model in which a stand-alone, didomain initiation
module comprised of a pHBA adenylation domain and an
aroyl carrier protein domain forms an acyl-S-enzyme cova-
lent intermediate in the p-hydroxyphenyl-polyketide chain
assembly line. The stand-alone status of this initiation mod-
ule sets it apart from related aryl acid primer unit didomain
loading systems characterized previously. Moreover, to
our knowledge, FadD22 is the first characterized, bona fide
pHBA-specific initiation module implicated in a polyketide
biosynthetic pathway. Lastly, the insights gained on the
mechanism of phenolphthiocerol biosynthesis initiation al-
lowed us to develop an inhibitor of PGL assembly with
potent activity in several mycobacterial pathogens. Overall,
these studies advance our understanding of the biosynthe-
sis of an important group of small-molecule effectors of
mycobacterial virulence and provide important support for
the feasibility of targeting PGL biosynthesis to develop
new drugs to treat mycobacterial infections.
EXPERIMENTAL PROCEDURES
Mycobacterial Strains and Growth Conditions
Mycobacteria were grown inMiddlebrook 7H9 (Difco) supplemented with 10%
albumin dextrose complex (Difco) and 0.1% Tween-80 or Middlebrook 7H11
plates (Difco) containing 10% oleic acid albumin dextrose complex (Difco).
M. tuberculosis Canetti, M. bovis BCG, and M. kansasii were cultured at
37C. M. marinum was cultured at 28C. When required, kanamycin (30 mg/ml),
hygromycin (50 mg/ml) and/or sucrose (2%) were added to the media.
DIM Production Analysis
Cultures grown for 8 d (M. tuberculosis and M. bovis) or 7 d (other species)
were diluted in fresh medium to an OD580 nm of 0.6 and loaded into 12 well
plates (1 ml/well). Wells were treated (in triplicate) with 0.8% DMSO (controls)
or pHB-AMS at different concentrations, and 0.8% DMSO. [1-C14]-propionate
(specific activity = 54mCi/mmol; ARC, Inc.) was added to eachwell at 0.2 mCi/ml
and plates were incubated for 12 hr before the OD of the cultures was mea-
sured and cells were harvested for apolar lipid extraction. Apolar lipids were
extracted with a biphasic mixture of methanolic saline and petroleum ether
(PE) as previously described (Onwueme et al., 2004, 2005b). PGLs in apolar
lipid extracts were analyzed by TLC on aluminum-backed 250 mm silica gel
plates (EMScience) with CHCl3/MeOH (95:5, v/v) eluent as previously reported
(Constant et al., 2002; Papa et al., 1987; Perez et al., 2004). PDIMs and
PNDIMs were analyzed by TLC with PE/diethyl ether (Et2O) (9:1, v/v) eluent
as previously reported (Onwueme et al., 2004; Onwueme et al., 2005b). Plates
were exposed to phosphor screens, which were scanned with a Typhoon Trio
Imager (Amersham Biosciences). PGL, PDIM, and PNDIM signals were quan-
tified with ImageQuant v1.2 (Molecular Dynamics). Dose-response graphs for
these and other experiments presented here were generated with Kaleido-
Graph 4.0. IC50 values were calculated by fitting the data to the sigmoid
equation:
Si
Sc
=b+
ða bÞ
1+ ð½I=IC50Þs
; (1)
where: Si and Sc are the background-corrected signals of the lipids in the
inhibitor-treated cultures and DMSO controls respectively; a and b are the
top and bottom of the curve, respectively; and s is the Hill coefficient.
Growth Inhibition Assay
Cultures grown for 7 dwere diluted inMiddlebrook 7H9 to anOD580 nm of 0.6 or
0.001 and loaded in 96well plates (200 ml/well). Wells were treated (in triplicate)
with 0.8%DMSO (controls) or pHB-AMS at different concentrations, and 0.8%58 Chemistry & Biology 15, 51–61, January 2008 ª2008 Elsevier LtdDMSO. Plates were incubated for growth for 10 d and OD580 nm wasmonitored
daily in a Spectra Max Plus reader (Molecular Dynamics).
Construction of a DfadD22 Mutant
The DfadD22 mutant was engineered by the p2NIL/pGOAL method as previ-
ously reported (Parish and Stoker, 2000) (Supplemental Experimental Proce-
dures). Briefly, we constructed a DfadD22 cassette-delivery suicide vector
carrying a deletion cassette that contains a 50 arm (1.2 kb region upstream
of fadD22 and fadD22’s start codon) and a 30 arm (fadD22’s last 10 codons
and the downstream 810 bp segment) (Figure S2). The C-terminal codons
were preserved due to sequence overlap with pks15/1. This vector was intro-
duced into M. bovis and mutants with fadD22 replaced by the DfadD22 cas-
sette via double-crossover were selected and identified by previously reported
methods (Onwueme et al., 2004; Parish and Stoker, 2000).
Plasmids for Protein Expression in Mycobacteria
pJAM-FadD22tb, pJAM-FadD22tbAd, and pJAM-FadD22ml were based on
the mycobacterial expression vector pJAM2 (Triccas et al., 1998) and express
the mycobacterial genes under control of the acetamidase promoter. pCP0-
FadD22tb, pCP0-FadD22tbAd, and pCP0-FadD22ml were based on the my-
cobacterial expression vector, pCP0, and express the mycobacterial genes
under control of the hsp60 promoter (Onwueme et al., 2004). See the Supple-
mental Experimental Procedures for plasmid construction.
pHB-AMP and pHB-CoA Formation
Reaction contained 75 mM MES [pH 6.5], 0.5 mM MgCl2, 1 mM TCEP, 50 mM
[14C]-pHBA, and, depending on the specific reaction indicated, combinations
of the following components: 1 mM ATP, 100 mM CoA, 0.5 mM Sfp, 5 mM
FadD22, 5 mM FadD22(S576A), or 5 mM BZLRp. Reactions were incubated for
2 hr at 30C and product formation was analyzed by radiometric TLC with Al
Sil G/UV TLC plates (Whatman) and ethyl acetate (EtOAc)/isopropyl alcohol/
acetic acid/water (70:20:25:40, v/v) eluent. Plates were exposed to phosphor
screens. The screens were scanned with a Typhoon Trio Imager and signal in-
tensity was quantified with ImageQuant v1.2 software. For time-course exper-
iments, pHB-AMP formation reactions (100 ml) containing 75mMMES [pH 6.5],
0.5 mMMgCl2, 1 mM TCEP, 1 mM ATP, 50 mM [
14C]-pHBA, and 2 mM of either
FadD22 or FadD22(S576A) were incubated at 30C. Reaction samples were
taken at different times for TLC analysis and pHB-AMP quantification. Concen-
trations of [14C]-pHB-AMP (or [14C]-pHB-CoA) were calculated with calibration
curves obtained by linear regression fitting to calibration data generated by
spotting known amounts of [14C]-pHBA on the plates after chromatography.
The identity of pHB-AMP and pHB-CoA products was confirmed by LC-MS
analysis of the (unlabeled) compounds isolated by preparative TLC. pHB-
CoA: [M + H]+m/z observed, 888.1432, calculated, 888.1436; [MH]m/z ob-
served, 886.1288, calculated, 886.1280; (data not shown). pHB-AMP: [M + H]+
m/z observed, 468.0916 (Figure 4A), calculated, 468.0915; [M  H] m/z
observed, 466.0769 (data not shown), calculated, 466.0769. The proteins
used in these and other experiments herewere expressed in E. coli and purified
as described in the Supplemental Experimental Procedures.
LC-MS Analysis
pHB-AMP and pHB-CoA were purified from pHB-AMP and pHB-CoA forma-
tion reactions, respectively, by preparative TLC. The product was eluted
with methanol, and the extract was subjected to LC-MS analysis. Other sam-
ples for LC-MS analysis were prepared as follows: reactions (100 ml) containing
5 mMMES [pH 6.5], 0.5 mMMgCl2, 1 mM TCEP, and, depending on the reac-
tion, 1 mM ATP, 1 mM pHBA, 1 mM CoA, and 10 mM of either FadD22 or
BZLRp, were incubated 2 hr at 30C in Mini Dialysis Units (Slide-A-Lyzer; cut-
off: 3.5 kDa; Pierce). Each unit was kept in contact with 100 ml of a reactionmix-
ture lacking enzyme so that released products accumulated in the enzyme-
free mixture, which was then subjected to LC-MS analysis. Samples were
analyzed on an Agilent Technologies 6210 high-resolution time-of-flight MS
connected to an Agilent Technologies 1200 capillary HPLC system. See the
Supplemental Experimental Procedures for details.
FadD22-pHB-AMP Complex Formation
pHB-AMP formation reactions containing 75mMMES [pH 6.5], 0.5mMMgCl2,
1 mM TCEP, 1 mM ATP, [14C]-pHBA, and 15 mM FadD22 were incubated forAll rights reserved
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trationG-50Macrospin Columns (The Nest Group, Inc.) equilibratedwith 75mM
MES [pH 6.5]. Columns were centrifuged (3 min, 110 3 g) and flowthrough
fractions were collected. The columns were then successively washed with al-
iquots of 75 mM MES [pH 6.5] (50 ml) and the flowthrough fractions were col-
lected. For each flowthrough fraction, a sample (5 ml) was subjected to TLC
analysis and pHB-AMP quantification, and a 10 ml sample was analyzed by
SDS-PAGE (12.5%). Gels were stained with GelCode Blue stain (Pierce) and
photographed. Densitometric analysis to quantify protein bands was per-
formed with Quantity One 4.5.2 software (Bio-Rad Laboratories).
In Vitro Phosphopantetheinylation
Reactions (50 ml) containing 75 mM Tris$HCl [pH 7.5], 10 mM MgCl2, 1 mM
TCEP, 1 mM CoA (40-phosphopanetheine-3H; 11 Ci/mmol; ARC, Inc.),
0.25 mM Sfp (absent in negative controls), and 0.75 mM of either FadD22,
FadD22(S576A), FadD22 coexpressed with Sfp, or FadD22(S576A) coex-
pressed with Sfp were incubated for 1 hr at 37C. After incubation, reactions
were diluted with 150 ml of PBS containing 20% MeOH, 1 mM CoA, and
0.1% BSA, and the mixtures were transferred to 96 well Ni2+-chelate-coated
FlashPlate Plus plates (Perkin Elmer). After tagged protein binding (overnight
at 4C), wells were washed with PBS (3 3 300 ml) and well-bound counts
were quantified in a Wallac Microbeta counter. Counts were converted to
amounts of phosphopantetheinylated protein with the specific activity of
[3H]-CoA. For time-dependent phosphopantetheinylation experiments, reac-
tions (50 ml) containing 75 mM Tris$HCl [pH 7.5], 10 mM MgCl2, 1 mM TCEP,
0.3 mM [3H]-CoA, 0.25 mM Sfp, and 1 mM of either FadD22 or FadD22(S576A)
were diluted as described above at different times and transferred to the plates
for protein binding and phosphopantetheinylation quantification.
In Vitro pHB-Protein Thioester Formation
Reactions (60 ml) containing 75 mMMES [pH 6.5], 0.5 mMMgCl2, 1 mM TCEP,
50 mM [14C]-pHBA, and, depending on the reaction indicated, 1 mM ATP,
100 mM CoA, and 10 mM of either FadD22, FadD22(S576A), FadD22 coex-
pressed with Sfp, or FadD22(S576A) coexpressed with Sfp were incubated
for 1 hr at 30C. After incubation, reaction aliquots (10 ml) were diluted with
PBS (15 ml) containing 2.5 mM pHBA and 20% MeOH. The mixtures were
transferred to nitrocellulosemembranes (pore size, 0.2 mm, Protran; Whatman)
for protein binding with Minifold I Slot Blot System (Whatman). Membranes
were washed sequentially with PBS containing 20% MeOH (3 3 25 ml) and
10% TCA (25 ml), and then exposed to phosphor screens. Phosphor screens
were scanned and signal intensity was quantified as described previously
here. Amounts of [14C]-pHB-protein thioester in the samples were calculated
with calibration curves obtained by linear regression fitting to calibration data
generated from known amounts of [14C]-pHBA spotted on the membranes.
An additional 4 ml aliquot was taken from each reaction and subjected to TLC
and pHB-AMP quantification as described previously here. For time-course ex-
periments, aliquots frompHB-protein thioester formation reactions (75mMMES
[pH 6.5], 0.5 mMMgCl2, 1 mM TCEP, 1 mM ATP, 50 mM [
14C]-pHBA, and 5 mM
FadD22 coexpressed with Sfp) taken at different times were diluted and ana-
lyzed for [14C]-pHB-protein thioester formation, as described previously here.
Inhibition of pHBA Adenylation
Reactions (20 ml) containing 75 mMMES [pH 6.5], 0.5 mMMgCl2, 1 mM TCEP,
1 mM ATP, 50 mM [14C]-pHBA, 2 mM FadD22, and 0.15% DMSO (controls) or
0.15% DMSO and pHB-AMS at different concentrations were incubated for
1 hr at 30C. After incubation, reaction aliquots were subjected to TLC analysis
and pHB-AMP quantification, as noted previously here. Sets of dose-response
data were fitted to the Morrison equation for tight-binding inhibitors
ni
nc
= 1
ð½E+ ½I+Kappi Þ 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð½E+ ½I+Kappi Þ24½E½I
q
2½E ; (2)
where E = enzyme; I = inhibitor; and vi and vc = velocities in the presence and
absence of inhibitor, respectively (Copeland, 2000). IC50 values were calcu-
lated with the equation for tight-binding inhibitors
IC50 =
1
2
½E+Kappi ; (3)Chemistry & Biologywith Kappi values derived from the curve fit (Copeland, 2000). The inhibitor used
in these and other studies described here was synthesized by 50-O-sulfamoy-
lation of a protected adenosine derivative, followed by N-acylation of the
sulfamate with p-acetoxybenzoic acid and removal of protecting groups
(see Supplemental Experimental Procedures and Figure S5).
Inhibition of pHB-Protein Thioester Formation
pHB-protein thioester formation reactions (20 ml) containing 75 mM MES [pH
6.5], 0.5 mM MgCl2, 1 mM TCEP, 1 mM ATP, 50 mM [
14C]-pHBA, 5 mM
FadD22 coexpressed with Sfp, and 0.15% DMSO (controls) or 0.15%
DMSO and pHB-AMS at different concentrations were routinely incubated
for 40 min at 30C. After incubation, 40 ml of PBS containing 20% MeOH
and 1 mM pHBA were added to each reaction, and 30 ml of each mixture
was transferred to nitrocellulose membranes for quantification of [14C]-pHB-
protein thioester in the samples, as noted previously here. Sets of dose-
response data were fitted to Equation 2 and IC50 values were calculated
with Equation 3, as described previously here.
Supplemental Data
Supplemental Data include five figures and additional Supplemental Experi-
mental Procedures used in this work and are available with this article online
at http://www.chembiol.com/cgi/content/full/15/1/51/DC1.
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